Nanoscope Therapeutics, Inc., a US-based clinical-stage biotechnology company, announced on Wednesday that it has named Naveed Shams MD, PhD, and Thomas Ciulla MD as advisors to the company's Board and Management.

Dr Shams has served as chief science officer at ProQR Therapeutics and earlier served as president and CEO of Santen Inc, and global head of R&D at Santen Pharmaceuticals. He has more than 25 years of global drug development experience across start-ups and large multinationals, including Novartis and Genentech/Roche. He has helped to set up the Ophthalmic Clinical R&D Group and led the development of Lucentis through approval at Genentech. He has served on the Faculty at the Department of Ophthalmology, Harvard Medical School.

Dr Ciulla has 25 years of experience in executive management, clinical research and academic leadership. He has held the position of chief medical officer and chief development officer at Clearside Biomedical. He has headed medical strategy through approval and commercialisation of Luxturna (voretigene), the first FDA-approved gene therapy for a hereditary retinal disease, which involved novel functional vision endpoints, complex genetic testing paradigms, and new administration procedures at Spark Therapeutics. He held the position of VP-Clinical Strategy at Ophthotech (now Iveric Bio).